The global cell line development market size was valued at USD 2.38 billion in 2014. Key growth drivers include the rising demand for monoclonal antibodies, increasing demand for effective cancer therapeutics and technological advancements introduced in this field.
Patent expiration of blockbuster drugs such as Lantus, Abilify, Namenda, and Androgel are expected to spur the entry of new biosimilars. In recent years on an average, around 15 novel proteins including therapeutic and recombinant proteins are being approved by the U.S. Food and Drug Administration (FDA) annually. Thus, high demand for novel drugs, vaccines, biosimilars, and therapeutic proteins is expected to boost the growth of the cell line development industry over the forecast period.
In addition, increasing vaccine production, growing healthcare expenditure levels, adoption of regenerative medicine and rise in funding pertaining to R&D in the biotechnology industry are few factors expected to boost future growth.
U.S. cell line development market, by type, 2012 - 2022 (USD Million)
Based on the type, the industry is segmented into hybridomas, recombinant, continuous, and primary. As of 2014, recombinant was the largest revenue generating segment due to its greater applicability in gene activation, protein interactions and biologics production over conventional cell assay methods.
Furthermore, rising demand for drug screening and toxicity testing are expected to increase growth potential for this segment. Hybridomas segment growth is expected to be in sync with the recombinant segment majorly owing to the capability of large scale continuous antibody production.
Reagents and media dominated the overall market in terms of revenue in 2014. Increasing bioproduction requiring reagents and media starting from incubation till line preservation and cost intensive nature are the factors attributing to its dominance over the forecast period.
Reagents used are antibiotics, attachments and matrix factors, biological buffers, cell separation, freezing and dissociation reagents, and miscellaneous reagents. Salts and media are instrumental in providing nutrients to the growing cells and are essential for proper growth. DMEM media, MEM media, Hans F-10 media, RPMI media, medium 199, and other classical media are commonly used media in cell development.
On the contrary, accessories and consumables segment is expected to witness a lucrative growth, owing to increasing usage of disposables in the cell line development procedure.
The mammalian source for product development dominated the overall demand in 2014 due to increasing adoption rates for the production of monoclonal antibodies and its ability to express complex proteins similar to human beings.
In addition, enhanced expression systems and engineering for mammalian cell source development are expected to fuel the market growth. There are over 4,000 mammalian lines available and research activities are going on for the introduction of few more.
The applications covered in this report include drug discovery toxicity testing, tissue engineering, and production of vaccines, monoclonal antibodies, bioproduction, and research. The products found major application in bioproduction comprising of vaccines, therapeutic proteins, and other biologics manufacturing.
In addition, an upsurge in R&D activities, the introduction of biosimilars and availability of technologically advanced processes for large scale production of biologics are expected to drive the growth of this application segment, in near future.
North America cell line development market was the largest with revenues at over USD 800 million in 2014. The presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining to product development, and rising awareness about therapeutic application of monoclonal antibodies in cancer treatment are some prominent drivers.
Asia Pacific market is expected to witness lucrative CAGR from 2015 to 2022 due to the presence of high untapped opportunities coupled with rapidly rising patient awareness regarding effective therapeutic procedures for cancer and rising research outsourcing trend from emerging economies of India and China.
Companies that dominate the global market share include Selexis SA, Lonza Group AG, Sartorious AG, GE Healthcare, Thermo Fisher Scientific Inc., European Collection of Cell Cultures (ECACC), Corning Inc., American Type Culture Collection (ATCC), WuXi AppTec Inc., and Sigma-Aldrich Corporation. The industry is competitive in nature marked by high industry rivalry levels. Players are striving to gain competitive advantage via capitalizing on available untapped opportunities.
Grand View Research offers special pricing for:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.